Moderna, Inc. vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
4.2
Underperform
Overall
7.3
Buy
Quality
Health
Growth
Valuation
Sentiment
MRNA
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-145% margin).
MRK
High-quality business with 37% return on equity and 28% profit margins.
⚠ earnings contracting 19% year-over-year.
Analyst Consensus
HOLD
Target $41.42 (-12.0%)
19 analysts
BUY
Target $129.74 (+17.6%)
27 analysts
Fundamentals
MRNA
MRK
—
Trailing P/E
15.1×
-9.9×
Forward P/E
11.4×
-145.2%
Profit Margin
28.1%
-105.8%
Gross Margin
77.2%
-28.9%
ROE
36.9%
-29.8%
Revenue Growth
5.0%
—
Earnings Growth
-19.3%
1.34
Beta
0.28
—
Price / Book
—
$18.7B
Market Cap
$272.4B
$22 – $60
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.